Kineta Chronic Pain LLC, announced today that the first participant has been successfully dosed in a Phase 1 multiple ascending dose (MAD) clinical trial of KCP506, an investigational, first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist in development for the treatment of chronic neuropathic pain.
The Phase 1, double blinded, placebo controlled, multiple ascending dose study is designed to evaluate the safety, tolerability, and pharmacokinetics of KCP506 in healthy people. The trial is designed to enroll up to 24 participants with safety, tolerability and pharmacokinetic data expected to read out in the second half of 2021. The company recently completed the single ascending dose (SAD) clinical study on KCP506.
“We are pleased to see KCP506 progress to the Phase 1 MAD clinical study after completing the single ascending dose earlier this year,” said Eric Tarcha PhD, Kineta EVP Research and Development. “There is such a tremendous unmet need for patients suffering from chronic neuropathic pain conditions. We are eager to see this novel non-opioid advance through clinical trials and hope it will one day be available for these patients in need.”
KCP506 may potentially be an effective treatment for many types of chronic neuropathic pain, including radiculopathy, chemotherapy-induced peripheral neuropathy, and diabetic neuropathy. α9α10 nAChR antagonists have demonstrated robust analgesic, anti-neuroinflammatory and neuroprotective effects across multiple preclinical chronic pain models. KCP506 offers the potential for a disease modifying therapy that may slow or halt the progression of chronic pain.